Previous close | 21.99 |
Open | 21.99 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 21.99 - 22.21 |
52-week range | 21.99 - 79.15 |
Volume | |
Avg. volume | 345 |
Market cap | 7.247M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | 0.17 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.